AAAAAA
Results: 1-25/57
Authors:
Ruiz, L
Negredo, E
Domingo, P
Paredes, R
Francia, E
Balague, M
Gel, S
Bonjoch, A
Fumaz, CR
Johnston, S
Romeu, J
Lange, J
Clotet, B
Citation: L. Ruiz et al., Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy, J ACQ IMM D, 27(3), 2001, pp. 229-236
Authors:
Vandamme, AM
Houyez, F
Banhegyi, D
Clotet, B
De Schrijver, G
De Smet, KAL
Hall, WW
Harrigan, R
Hellmann, N
Hertogs, K
Holtzer, C
Larder, B
Pillay, D
Race, E
Schmit, JC
Schuurman, R
Shulse, E
Sonnerborg, A
Miller, V
Citation: Am. Vandamme et al., Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up, ANTIVIR TH, 6(1), 2001, pp. 21-39
Authors:
Casado, E
Olive, A
Holgado, S
Perez-Andres, R
Romeu, J
Lorenzo, JC
Clotet, B
Tena, X
Citation: E. Casado et al., Musculoskeletal manifestations in patients positive for human immunodeficiency virus: Correlation with CD4 count, J RHEUMATOL, 28(4), 2001, pp. 802-804
Authors:
Ruiz, L
Carcelain, G
Martinez-Picado, J
Frost, S
Marfil, S
Paredes, R
Romeu, J
Ferrer, E
Morales-Lopetegi, K
Autran, B
Clotet, B
Citation: L. Ruiz et al., HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection, AIDS, 15(9), 2001, pp. F19-F27
Authors:
Kirk, O
Mocroft, A
Pradier, C
Bruun, JN
Hemmer, R
Clotet, B
Miller, V
Viard, JP
Phillips, AN
Lundgren, JD
Citation: O. Kirk et al., Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir, AIDS, 15(8), 2001, pp. 999-1008
Authors:
Miller, V
Vandamme, AM
Loveday, C
Staszewski, S
Lundgren, J
Youle, M
Ait-Khaled, M
Boucher, C
Brun-Vezinet, F
Dedes, N
Giaquinto, C
Hertogs, K
Houyez, F
Perrin, L
Pillay, D
Schmit, JC
Schuurman, R
Lange, J
Banhegyi, D
Biondi, G
Broekhuizen, A
Bush-Donovan, C
Camacho, R
Carlier, H
Clavel, F
Clotet, B
Clumeck, N
Colebunders, R
De Clerq, K
De Jaegher, JJ
De Schrijver, G
De Smet, K
Hall, W
Harrigan, R
Hatzakis, A
Hellmann, N
Hoetelmans, R
Holtzer, C
Katlama, C
Larder, D
Loriaux, E
McCreedy, B
Mulcahy, F
Opravil, M
Phillips, A
Ruiz, N
Shulse, E
Sonnerborg, A
Soriano, V
Steel, H
Vella, S
Williams, A
Citation: V. Miller et al., Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting, AIDS, 15(3), 2001, pp. 309-320
Authors:
Llano, A
Barretina, J
Blanco, J
Gutierrez, A
Clotet, B
Este, JA
Citation: A. Llano et al., Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo, AIDS, 15(14), 2001, pp. 1890-1892
Authors:
Gallego, O
Ruiz, L
Vallejo, A
Ferrer, E
Rubio, A
Clotet, B
Leal, M
Soriano, V
Citation: O. Gallego et al., Changes in the rate of genotypic resistance to antiretroviral drugs in Spain, AIDS, 15(14), 2001, pp. 1894-1896
Authors:
Tuldra, A
Fumaz, CR
Ferrer, MJ
Paredes, R
Romeu, J
Ruiz, L
Bayes, R
Clotet, B
Citation: A. Tuldra et al., Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads, AIDS, 15(14), 2001, pp. 1904-1906
Authors:
Perez-Olmeda, M
Del Romero, J
Rubio, A
Ruiz, L
Rodriguez, C
Leal, M
Clotet, B
Soriano, V
Citation: M. Perez-olmeda et al., Primary HIV-1 drug resistance in spain before and after the introduction of protease inhibitors, J MED VIROL, 63(2), 2001, pp. 85-87
Authors:
Blanco, J
Barretina, J
Cabrera, C
Gutierrez, A
Clotet, B
Este, JA
Citation: J. Blanco et al., CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro, VIROLOGY, 285(2), 2001, pp. 356-365
Authors:
Ibanez, A
Clotet, B
Martinez, MA
Citation: A. Ibanez et al., Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy, VIROLOGY, 282(1), 2001, pp. 1-5
Authors:
Llano, A
Barretina, J
Gutierrez, A
Blanco, J
Cabrera, C
Clotet, B
Este, JA
Citation: A. Llano et al., Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals, J VIROLOGY, 75(21), 2001, pp. 10319-10325
Authors:
Tuldra, A
Fumaz, CR
Ferrer, MJ
Bayes, R
Arno, A
Balague, M
Bonjoch, A
Jou, A
Negredo, E
Paredes, R
Ruiz, L
Romeu, J
Sirera, G
Tural, C
Burger, D
Clotet, B
Citation: A. Tuldra et al., Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy, J ACQ IMM D, 25(3), 2000, pp. 221-228
Authors:
Garcia, F
Alonso, MM
Romeu, J
Knobel, H
Arrizabalaga, J
Ferrer, E
Dalmau, D
Ruiz, I
Vidal, F
Frances, A
Segura, F
Gomez-Sirvent, JL
Cruceta, A
Clotet, B
Pumarola, T
Gallart, T
O'Brien, WA
Miro, JM
Gatell, JM
Citation: F. Garcia et al., Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish Earth-2 Study, J ACQ IMM D, 25(1), 2000, pp. 26-35
Authors:
Puig-Basagoiti, F
Cabana, M
Guilera, M
Gimenez-Barcons, M
Sirera, G
Tural, C
Clotet, B
Sanchez-Tapias, JM
Rodes, J
Saiz, JC
Martinez, MA
Citation: F. Puig-basagoiti et al., Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV, J ACQ IMM D, 23(1), 2000, pp. 89-94
Authors:
Mocroft, A
Miller, V
Chiesi, A
Blaxhult, A
Katlama, C
Clotet, B
Barton, S
Lundgren, JD
Citation: A. Mocroft et al., Virological failure among patients on HAART from across Europe: results from the EuroSIDA study, ANTIVIR TH, 5(2), 2000, pp. 107-112
Authors:
Van Laethem, K
Schmit, JC
Pelemans, H
Balzarini, J
Witvrouw, M
Perez-Perez, MJ
Camarasa, MJ
Esnouf, RM
Aquaro, S
Cenci, A
Perno, CF
Hermans, P
Sprecher, S
Ruiz, L
Clotet, B
Van Wijngaerden, E
Van Ranst, M
Desmyter, J
De Clercq, E
Vandamme, AM
Citation: K. Van Laethem et al., Presence of 2 ',5 '-bis-O-(tert-butyldimethylsilyl)-3 '-spiro-5 ''-(4 ''-amino-1 '',2 ''-oxathiole-2 '',2 ''-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients, AIDS RES H, 16(9), 2000, pp. 825-833
Authors:
Cabrera, C
Gutierrez, A
Blanco, J
Barretina, J
Litovchick, A
Lapidot, A
Evdokimov, AG
Clotet, B
Este, JA
Citation: C. Cabrera et al., Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection, AIDS RES H, 16(7), 2000, pp. 627-634
Authors:
Van Vaerenbergh, K
Van Laethem, K
Van Wijngaerden, E
Schmit, JC
Schneider, F
Ruiz, L
Clotet, B
Verhofstede, C
Van Wanzeele, F
Muyldermans, G
Simons, P
Stuyver, L
Hermans, P
Evans, C
De Clercq, E
Desmyter, J
Vandamme, AM
Citation: K. Van Vaerenbergh et al., Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy, AIDS RES H, 16(6), 2000, pp. 529-537
Authors:
Katlama, C
Clotet, B
Plettenberg, A
Jost, J
Arasteh, K
Bernasconi, E
Jeantils, V
Cutrell, A
Stone, C
Ait-Khaled, M
Purdon, S
Citation: C. Katlama et al., The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial, AIDS, 14(7), 2000, pp. 781-789
Authors:
Puig, T
Perez-Olmeda, M
Rubio, A
Ruiz, L
Briones, C
Franco, JM
Gomez-Cano, M
Stuyver, L
Zamora, L
Alvarez, C
Leal, M
Clotet, B
Soriano, V
Citation: T. Puig et al., Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain, AIDS, 14(6), 2000, pp. 727-732
Authors:
Gartland, M
Gerstoft, J
Goebel, F
Clumeck, N
Cooper, DA
Gatell, J
Gazzard, B
Gerstoft, J
Goebel, F
Lange, J
Montaner, J
Reiss, P
Rozenbaum, W
Vella, S
Beveridge, A
Cooper, DA
Duncombe, C
Gold, J
Haberl, M
Clumeck, N
Luyts, D
Montaner, J
Rachlis, A
Marina, R
Gerstoft, J
Wandall, JH
Elbrond, B
Molina, JM
Pialloux, G
Rozenbaum, W
Beauvais, L
Goebel, FD
Staszewski, S
Bruns, I
Hug, M
Reiss, P
Lange, J
Frissen, PHJ
van der Ende, ME
Bosboom, M
Baas, C
Milazzo, F
Moroni, M
Panebianco, R
Clotet, B
Artigas, JMG
Gonzalez-Lahoz, J
Leal, M
Rodriguez-Lopo, C
Gandarias, B
Gazzard, B
Johnson, M
McKinley, S
Page, V
Watkins, K
Sandstrom, E
Belsey, E
Darbyshire, J
Chodakewitz, J
Isaacs, R
Jonas, L
Meibohm, A
Coughlan, M
Fiddian, P
Gartland, M
Harrigan, R
Larder, B
Maguire, M
Millard, J
Moore, S
Patel, K
Shortino, D
Tisdale, M
Vafidis, I
Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
Authors:
Ruiz, L
Martinez-Picado, J
Romeu, J
Paredes, R
Zayat, MK
Marfil, S
Negredo, E
Sirera, G
Tural, C
Clotet, B
Citation: L. Ruiz et al., Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression, AIDS, 14(4), 2000, pp. 397-403
Authors:
Van Laethem, K
Witvrouw, M
Balzarini, J
Schmit, JC
Sprecher, S
Hermans, P
Leal, M
Harrer, T
Ruiz, L
Clotet, B
Van Ranst, M
Desmyter, J
De Clercq, E
Vandamme, AM
Citation: K. Van Laethem et al., Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir, AIDS, 14(4), 2000, pp. 469-471